NAV

2-chloroethyl-3-sarcosinamide-1-nitrosourea

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
2-chloroethyl-3-sarcosinamide-1-nitrosourea
DrugBank Accession Number
DB11688
Background

2-chloroethyl-3-sarcosinamide-1-nitrosourea has been used in trials studying the treatment of Colorectal Cancer, Brain and Central Nervous System Tumors, and Unspecified Adult Solid Tumor, Protocol Specific.

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 222.63
Monoisotopic: 222.0519679
Chemical Formula
C6H11ClN4O3
Synonyms
  • 2-chloroethyl-3-sarcosinamide-1-nitrosourea
  • ACETAMIDE, 2-((((2-CHLOROETHYL)NITROSOAMINO)CARBONYL)METHYLAMINO)-
  • SarCNU
  • SARCOSINEAMIDE CHLOROETHYLNITROSOUREA
  • Sarmustine
External IDs
  • NSC 364432
  • NSC-364432
  • NSC364432
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AmbroxolThe risk or severity of methemoglobinemia can be increased when SarCNU is combined with Ambroxol.
ArticaineThe risk or severity of methemoglobinemia can be increased when 2-chloroethyl-3-sarcosinamide-1-nitrosourea is combined with Articaine.
BenzocaineThe risk or severity of methemoglobinemia can be increased when 2-chloroethyl-3-sarcosinamide-1-nitrosourea is combined with Benzocaine.
Benzyl alcoholThe risk or severity of methemoglobinemia can be increased when 2-chloroethyl-3-sarcosinamide-1-nitrosourea is combined with Benzyl alcohol.
BupivacaineThe risk or severity of methemoglobinemia can be increased when 2-chloroethyl-3-sarcosinamide-1-nitrosourea is combined with Bupivacaine.
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as alpha amino acids and derivatives. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon), or a derivative thereof.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Alpha amino acids and derivatives
Alternative Parents
Nitrosoureas / Semicarbazides / Nitrosamides / Primary carboxylic acid amides / Organopnictogen compounds / Organochlorides / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds / Alkyl chlorides
Substituents
Aliphatic acyclic compound / Alkyl chloride / Alkyl halide / Alpha-amino acid or derivatives / Carbonic acid derivative / Carbonyl group / Carboxamide group / Hydrocarbon derivative / Nitrosamide / Nitrosourea
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
BHB013S3MO
CAS number
81965-43-7
InChI Key
HYHJFNXFVPGMBI-UHFFFAOYSA-N
InChI
InChI=1S/C6H11ClN4O3/c1-10(4-5(8)12)6(13)11(9-14)3-2-7/h2-4H2,1H3,(H2,8,12)
IUPAC Name
2-{[N-(2-chloroethyl)-N'-oxohydrazinecarbonyl](methyl)amino}acetamide
SMILES
CN(CC(N)=O)C(=O)N(CCCl)N=O

References

General References
Not Available
Human Metabolome Database
HMDB0257494
PubChem Compound
100773
PubChem Substance
347828054
ChemSpider
91053
ChEMBL
CHEMBL166937
ZINC
ZINC000003811824

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
2CompletedTreatmentBrain and Central Nervous System Tumors1
2CompletedTreatmentColorectal Cancer1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility3.81 mg/mLALOGPS
logP-0.06ALOGPS
logP-0.75Chemaxon
logS-1.8ALOGPS
pKa (Strongest Acidic)15.31Chemaxon
pKa (Strongest Basic)-4.5Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area96.07 Å2Chemaxon
Rotatable Bond Count5Chemaxon
Refractivity50.44 m3·mol-1Chemaxon
Polarizability19.64 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-014i-3900000000-77e7a4d17fbc874c81b7
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-00dr-9370000000-18e8019b596d2d0eee61
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-00di-5090000000-a66e4e6b95dee87dbf8e
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-9000000000-c6fd26ec267c6ccd747b
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-00di-9200000000-cfbed0ded3f3a0d13dc3
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9000000000-e79f790495328b5236cc
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-00di-9100000000-08e4bbe5aabe7fe1e5b6
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-140.4063
predicted
DeepCCS 1.0 (2019)
[M+H]+143.10219
predicted
DeepCCS 1.0 (2019)
[M+Na]+151.58226
predicted
DeepCCS 1.0 (2019)

Drug created at October 20, 2016 20:40 / Updated at July 18, 2023 22:56